6,7-dichloro-2-cyclopentyl-2-methyl-5-[4-(pyridin-3-yloxy)butoxy]indan-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 6,7-dichloro-2-cyclopentyl-2-methyl-5-[4-(pyridin-3-yloxy)butoxy]indan-1-one
• 英文别名: 6,7-dichloro-2-cyclopentyl-2-methyl-5-(4-pyridin-3-yloxybutoxy)-3H-inden-1-one
• 化学式: C₂₄H₂₇Cl₂NO₃
• 分子量: 448.389
• InChiKey: GTGGJJYVLWQEPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-羟基吡啶 、 5-(4-bromobutoxy)-6,7-dichloro-2-cyclopentyl-2-methylindan-1-one 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 16.0h， 生成 6,7-dichloro-2-cyclopentyl-2-methyl-5-[4-(pyridin-3-yloxy)butoxy]indan-1-one
  参考文献：
  名称：

  WO2006/47237

  摘要：

  公开号：

文献信息

• Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors
  申请人：Pinkerton B. Anthony

  公开号：US20080096935A1

  公开（公告）日：2008-04-24

  The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及一种激活型代谢型谷氨酸受体的化合物，包括mGluR2受体，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型谷氨酸受体的疾病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及代谢型谷氨酸受体的疾病中使用这些化合物和组合物。
• HETEROCYCLIC INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Merck & Co., Inc.

  公开号：EP1807073A2

  公开（公告）日：2007-07-18
• [EN] HETEROCYCLIC INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] POTENTIALISATEURS INDANONE HETEROCYCLIQUES DES RECEPTEURS METABOTROPIQUES DU GLUTAMATE
  申请人：MERCK & CO INC

  公开号：WO2006047237A2

  公开（公告）日：2006-05-04

  [EN] The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
  [FR] La présente invention se rapporte à des composés qui sont des potentialisateurs des récepteurs métabotropiques du glutamate, notamment du récepteur mGluR2, et qui sont utiles pour le traitement ou la prévention des troubles neurologiques et psychiatriques associés à un dysfonctionnement du glutamate et à des maladies dans lesquelles sont impliquées les récepteurs métabotropiques du glutamate. L'invention se rapporte également à des compositions pharmaceutiques comportant ces composés, ainsi qu'à l'utilisation de ces composés et compositions pour la prévention et le traitement des maladies dans lesquelles sont impliquées les récepteurs métabotropiques du glutamate.
• WO2006/47237
  申请人：——

  公开号：——

  公开（公告）日：——